Category: Clinical Trial Operations (Trial Start-up, Regulatory, Data Management, IITs) – Completed Project

Operationalizing CTSU's Protocol and CIRB Update Listing for Processing Local Regulatory Documents

E. Arnold, J. Rarden, A. Willingham

The University of Kansas Cancer Center

1. Background

Regulatory documents for studies overseen by the National Cancer Institute (NCI) Central Institutional Review Board (CIRB) must be processed and activated within 30 days of posting to the Clinical Trials Support Unit (CTSU) website. The University of Kansas Cancer Center (KUCC) Clinical Trials Office (CTO) regulatory team manages over 200 National Cancer Trials Network (NCTN) and Experimental Therapeutics Clinical Trials Network (ETCTN) studies. Staying on top of the posts proved difficult for a smaller staff of four from 2015 to 2019. At the time of development, CTSU's Dashboard feature filtered to all CIRB-approved studies for the site, which made it difficult for coordinators to focus on only the subset of studies each coordinator managed. The manager of the regulatory team and one of the regulatory coordinators worked together to develop a better method to track and distribute these updates to individual coordinators.

2. Goals

- Avoid missing important regulatory updates.
- Process amendments within 30 days of posting.

3. Solutions and Methods

An Excel-savvy regulatory coordinator developed a smart spreadsheet to map protocol updates posted on CTSU to the studies maintained by the KUCC regulatory team.

The report is updated by our NCTN administrator. She exports both Protocol Updates and CIRB Updates from CTSU to Excel once a week. Only postings from the previous week are pasted into the mapping spreadsheet. The columns used are Date, Protocol ID, and Update description. In addition, the CTO's Research Systems team distributes two weekly reports (start-up and maintenance) of all CTO-managed studies from our Clinical Trial Master System. This report includes the Disease Working Group, Study Status, IRB number, Protocol ID, Principal Investigator, IRB Expiration Date, and Regulatory Contact. These reports are also pasted into the mapping spreadsheet.

Studies not managed by KUCC populate with an N/A and are filtered out of the report. The resulting report includes all updates posted to CTSU for the prior week for only those studies maintained by our regulatory coordinators. The NCTN administrator pastes the table into an email and distributes it to the regulatory coordinators, manager, and program director.

4. Outcomes

Amendment processing timelines from CTSU posting to local activation improved from an average of 25.5 days to 11.9 days after implementation of the report. The team saw a high of 17 audit findings for delayed activation in 2017 to no regulatory audit findings in 2023.

5. Lessons Learned and Future Directions

A few errors have occurred since implementation, including new studies not being added to the Lookup mapping tab and typographical errors in Protocol IDs on the Lookup tab which made some studies show as N/A. This resulted in two instances of missed amendments.

Category: Clinical Trial Operations (Trial Start-up, Regulatory, Data Management, IITs) – Completed Project

In 2022, we implemented having each regulatory coordinator's functional manager review the report weekly to ensure items are processed within the 30-day window required for NCI CIRB studies. Staff are also instructed that the report is a second check and should not be the sole source of truth for protocol and CIRB updates on the studies they maintain.

While the CTSU Dashboard can now be filtered to a coordinator's selected studies, the weekly report allows for cross-coverage when coordinators are out and enables managers to track the work being completed on the team.

Figure

Home Protocols 🗇 Dashboard		ý				0440	+1 Se	wdy Status 🔍	Stady Namber v	Sponsor ID v	Pl V Date	Pegulatery Contact
Notifications	# Date	Proto	col	Update		Brain	Teld Status - Arrive	uEwelling				1.25 Raches West
TRI No new notifications	1 21-Feb-2025 NH		Memorandum: Notice of S	Sample Collection								
	2 20-Feb-202	5 NRG-BROOS	Discontinuation for the N Mentorandum: Webinar J	Announcement			Trial Status - Follow	e-up/Clased To				
Protocol Updates CIRB Updates	3 20-Feb-202	5 NRG-HN014	Memorandum: Updated E Submission Manual and C			Bran	Englinent					Sto Pranda Continues
All Protocols		5 A032102	Memorandum: PREDICT	Informational Webin	ar		Trial Status - Follow					
	5 19-Feb-202		CTSU PROTOCOL ACTIVA			Brain	Engliment	and a second s		into Trige Turner	2	and Alata Manadaana
🕑 🖉 L 🔸 H 🕹 🔺	6 18-Feb-202		Memorandum: Upcoming									
Export PDF Export Excel	7 17-Feb-202	5 \$2308	Memorandum: SWOG Phi _ Initial Order Build Form	armacy Committee T as Group	ask Force						Mapping Sp	preadsheet
Export Excel (CSV)				Pretocol:	P-001 Eligible " DWG		v Study Status	-1	idy Number	sor ID v Principal Investigator	v HSC Expirativ v B	Regulatory Contact
Refresh At				NRS-BN011 TRI	e Brain		Trial Status - Active/Enro					echeal West
				N0577 TRI	a Brain		Trial Status - Follow-up/I					liranda Olenhouse
				NRG-BN010 FAI	SE Brain	C.C.C. and an United St.	Trial Status - Follow-up/I	Clased To Enrollment 2	JL.	Noto Tolga Tuncer	6 Mor-2514	Incla Montelezere
	Date	Protocol	Update		DWG	STUDY_STA	TUS	HSC_NUMBER	SPONSORID	PRINCIPAL_INVESTIGATOR	HSC EXPIRATION DATE	E Regulatory Contact
	21-Feb-2025	1	Memorandum: Notice of Sample Collectio the NHLB1-MDS Study	n Discontinuation for					-	1		1
	20-Feb-2025 20-Feb-2025		Memorandum: Webinar Announcement Memorandum: Undated Biospecimen Coll-	ection and	Breast RadOnc	Trial Status	- Active/Enrolling	STUDY0015009				
			Submission Manual and Clarification for S Biopsy Blocks	ites Unable to Submit								
	19-Feb-2025 19-Feb-2025		Memorandum: PREDICT Informational W CTSU PROTOCOL ACTIVATION	Vebinar	GU	Trial Status	- Active/Enrolling	STUDY0016119				
	18-Feb-2025		Memorandum: Upcoming Study Closure		GU	Trial Status	- Active/Enrolling	STUDY0014348				
	17-Feb-2025	S2308	Memorandum: SWOG Pharmacy Committ Initial Order Build Focus Group	tee Task Force –	Lymphoma/Myeloma	Trial Status	- Active/Enrolling	STUDY0016096	1 \$2308	Marc Hoffmann	5/7/2025	Anne Roland
	17-Feb-2025	S2308	Memorandum: SWOG Pharmacy Committ			Trial Status		Fernand E THE 2710/2015 SHIT AM	2 EAS371 1 52308	Votilisam Partier Marc Hoffmann		